Amyris, Inc. announced that Philip Eykerman?s decision to resign from the Company?s Board of Directors (the ?Board ?), effective immediately. Mr. Eykerman had been serving on the Board since May 2017 as a designee of DSM in connection with the right of DSM to designate directors pursuant to the Amended and Restated DSM Stockholder Agreement, dated as of August 7, 2017, by and between DSM and the Company. DSM?s designation rights terminate at such time as DSM beneficially owns less than 4.5% of the Company?s outstanding common stock.

DSM currently owns approximately 4.5% of the Company?s outstanding common stock on a beneficial ownership basis. Mr. Eykerman?s resignation is not the result of any disagreement with the Company or due to any matter relating to its operations, policies or practices.